Regenxbio Inc [RGNX] stock is trading at $12.71, up 18.34%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RGNX shares have gain 17.47% over the last week, with a monthly amount drifted -7.29%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Regenxbio Inc [NASDAQ: RGNX] stock has seen the most recent analyst activity on June 07, 2024, when Goldman initiated its Buy rating and assigned the stock a price target of $38. Previously, H.C. Wainwright started tracking the stock with Buy rating on March 11, 2024, and set its price target to $36. On March 08, 2024, upgrade upgraded it’s rating to Outperform and revised its price target to $35 on the stock. Leerink Partners upgraded its rating to a Outperform but stick to its price target of $37 on March 06, 2024. Stifel started tracking with a Buy rating for this stock on November 01, 2023, and assigned it a price target of $35. In a note dated June 02, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $42 on this stock.
Regenxbio Inc [RGNX] stock has fluctuated between $10.49 and $28.80 over the past year. Currently, Wall Street analysts expect the stock to reach $37.75 within the next 12 months. Regenxbio Inc [NASDAQ: RGNX] shares were valued at $12.71 at the most recent close of the market. An investor can expect a potential return of 197.01% based on the average RGNX price forecast.
Analyzing the RGNX fundamentals
Regenxbio Inc [NASDAQ:RGNX] reported sales of 86.73M for the trailing twelve months, which represents a drop of -18.37%. Gross Profit Margin for this corporation currently stands at 0.47% with Operating Profit Margin at -3.04%, Pretax Profit Margin comes in at -3.0%, and Net Profit Margin reading is -3.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.71 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.53 points at the first support level, and at 10.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.47, and for the 2nd resistance point, it is at 14.23.
Ratios To Look Out For
For context, Regenxbio Inc’s Current Ratio is 3.59. Further, the Quick Ratio stands at 3.59, while the Cash Ratio is 1.03. Considering the valuation of this stock, the price to sales ratio is 7.22, the price to book ratio is 1.60.
Transactions by insiders
Recent insider trading involved KARABELAS ARGERIS N, Director, that happened on Jul 01 ’24 when 10000.0 shares were sold. President and CEO, Mills Kenneth T. completed a deal on May 14 ’24 to sell 15000.0 shares. Meanwhile, President and CEO Mills Kenneth T. sold 15000.0 shares on Apr 15 ’24.
